Discontinued — last reported Q3 '24
Inmazeb — Revenue
Year-over-year, this metric grew by 978.8%, from $3.30M to $35.60M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration, higher patient adoption, or effective commercial execution for the specific therapy, while a decrease may signal increased competition, loss of market exclusivity, or declining clinical demand.
Detailed definition
This metric represents the total net sales generated from the commercialization of a specific therapeutic product indica...
Peer comparison
Similar to product-specific revenue lines reported by other biopharmaceutical companies, this metric is comparable to revenue from orphan drugs or specialized infectious disease treatments at peer firms.
regn_segment_inmazeb_revenuesHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|
| Value | $2.20M | $2.20M | $3.30M | $1.00M | $0.00 | $35.60M |
| QoQ Change | — | +0.0% | +50.0% | -69.7% | -100.0% | — |
| YoY Change | — | — | — | -54.5% | -100.0% | +978.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's inmazeb — revenue?
- Regeneron Pharmaceuticals (REGN) reported inmazeb — revenue of $35.60M in Q3 2024.
- How has Regeneron Pharmaceuticals's inmazeb — revenue changed year-over-year?
- Regeneron Pharmaceuticals's inmazeb — revenue increased by 978.8% year-over-year, from $3.30M to $35.60M.
- What does inmazeb — revenue mean?
- The total revenue earned from sales of a specific pharmaceutical product.